Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling

Author(s): Steingrimur Stefansson, Grainne A. McMahon, Eric Petitclerc, Daniel A. Lawrence

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 19 , 2003

Become EABM
Become Reviewer


Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of urokinase type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA), and as such is thought to play an important role in the regulation of extracellular matrix remodeling. In blood, PAI-1 is bound to the adhesion protein vitronectin and is associated with vitronectin in fibrin clots and the provisional matrix. Elevated levels of PAI-1 are associated with atherosclerosis and an increased thrombotic tendency, while PAI-1 deficiency leads to increased fibrinolysis and bleeding. PAI-1 is also elevated in many solid tumors and is associated with a poor prognosis in cancer. PAI-1 has been shown to be a potent regulator of both vascular cell migration in vitro and of angiogenesis and tumor growth in vivo. PAI-1 can both promote and inhibit tumor growth and angiogenesis. Low concentrations of PAI-1 can stimulate tumor angiogenesis while treatment of animals with high doses of PAI-1 inhibits angiogenesis and tumor growth. Hence, PAI-1 appears to have a multifunctional role in regulating the migratory and fibrinolytic activity of vascular cells, and this, in turn, may help to explain the many varied actions of PAI-1.

Keywords: plasminogen activator inhibitor-1, pai-1, serpin, plasminogen, vitronectin, angiogenesis, migration, tumor, fibrinolysis, extracellular matrix remodeling

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [1545 - 1564]
Pages: 20
DOI: 10.2174/1381612033454621
Price: $65

Article Metrics

PDF: 23